ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/neuroendocrine-tumours/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Sarcoma, Endocrine, and Rare Cancers / Neuroendocrine tumours - Advanced/metastatic
9
trial(s) found.
NCT07713732
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors (
TLN-499-2601
)
Bcl-xL degrader
Bcl2 inhibitor
Neuroendocrine tumour
Pleural mesothelioma
Small-cell lung cancer
Synovial sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07544654
Advanced
Phase 3
Recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas (
1438-0011
)
bispecific T-cell engager,DLL3-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
Lung neuroendocrine tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07369505
Advanced
Phase 1
Recruiting
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane) (
SP-03-B101
)
aromatase inhibitor
mTORC1/mTORC2 inhibitor
Breast cancer
Clear cell renal cell carcinoma
Hepatocellular carcinoma
Neuroendocrine tumour
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06943755
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors (
STELLAR-311
)
MET/VEGFR2/AXL/MER inhibitor
mTORC1 inhibitor
Pancreatic neuroendocrine tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06345079
Advanced
Phase 2
Recruiting
A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (
STOPNET
)
Octreotide
cancer therapy
endocrine therapy
endocrine therapy,somastatin axis-targeting
somatostatin analog
Neuroendocrine tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4350 - Toowoomba - Toowoomba Hospital
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
6430 - Kalgoorlie-Boulder - Kalgoorlie Health Campus
NCT05053854
Radonc
Phase 1
Recruiting
Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor (
PARLuNET
)
radioconjugate,DOTA-targeting
Neuroendocrine tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04924075
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations (
6482-015
)
HIF2a inhibitor
Gastrointestinal stromal tumour
Pancreatic neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12621000802808
Advanced
Phase 2
Recruiting
A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults. (
LU-TEMP
)
alkylating agent
Paraganglioma
Phaeochromocytoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
ACTRN12610000440022
Radonc
Phase 2
Recruiting
CLEMENT
Capecitabine-radiosensitizing Lutetium-177 octreotate endoradiotherapy management of endocrine neurogenic tumours Response and Toxicity Assessment
fluoropyrimidine
Neuroendocrine tumour
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (9)
Recruitment Country and State
NSW (6)
VIC (6)
WA (5)
SA (4)
QLD (2)
NZ (1)
Phase
Phase 1 (3)
Phase 2 (4)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Advanced (7)
Radonc (2)
Cancer Therapy Class
mTOR
22%
mTORC1
22%
Bcl2
11%
DLL3
11%
mTORC2
11%
oestrogen axis
11%
AXL
11%
MER
11%
MET
11%
VEGFR2
11%
somastatin axis
11%
HIF2a
11%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
5042 - Bedford Park - Flinders Medical Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
2500 - Wollongong - Wollongong Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
6430 - Kalgoorlie-Boulder - Kalgoorlie Health Campus (1)
2031 - Randwick - Prince of Wales Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
Cancer Type
Cancer
Neuroendocrine tumour
Solid tumour
Gastrointestinal cancer
Upper gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Thoracic cancer
Gastro-entero-pancreatic neuroendocrine tumour
Pancreatic cancer
Pancreatic neuroendocrine tumour
Pancreatobiliary cancer
Adrenal cancer
Endocrine gland cancer
Paraganglioma
Phaeochromocytoma
Carcinoma
Mesothelioma
Neuroendocrine carcinoma
Pleural mesothelioma
Sarcoma
Sarcoma, synovial-like
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Synovial sarcoma
Lung neuroendocrine tumour
Breast cancer
Clear cell renal cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Kidney cancer
Urogenital cancer
Gastrointestinal stromal tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy